BTA-EG4

• UNSPSC Description:

  BTA-EG4 is a catalase-amyloid interaction inhibitor, which can significantly enhance the neurotoxicity of amyloid peptides in catalase-overexpressing neuronal cells, and can be used in the study of neurodegenerative diseases[1].

• Target Antigen:

  Amyloid-β; Reactive Oxygen Species

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease;Neuronal Signaling;NF-κB

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/bta-eg4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=CC=C2N=C(C3=CC=C(NCCOCCOCCOCCO)C=C3)SC2=C1

• Molecular Weight:

  416.53

• References & Citations:

  [1]Amrutha Chilumuri, et al. Benzothiazole Aniline Tetra(ethylene glycol) and 3-Amino-1,2,4-triazole Inhibit Neuroprotection against Amyloid Peptides by Catalase Overexpression in Vitro.Amrutha Chilumuri, Mark Odell, and Nathaniel G. N. Milton.ACS Chemical Neuroscience 2013 4 (11), 1501-1512.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  921193-28-4